Skip to main content
. Author manuscript; available in PMC: 2013 Feb 1.
Published in final edited form as: Mol Genet Metab. 2011 Nov 7;105(2):203–211. doi: 10.1016/j.ymgme.2011.10.020

Figure 2. Dose correlated OTC protein expression levels and vector genomes in liver.

Figure 2

Figure 2

Livers were harvested from vector-treated spfash and untreated control mice at 4, 13, and 40 weeks (1×1011, 3×1010 and 1×1010 GC groups) or 6 and 23 weeks (3×109 and 1×109 GC groups) post vector treatment. (a) Western blot analysis on liver lysates from WT, vector-treated (4 or 6 weeks post) or untreated spfash mice (1 μg, 0.1 μg or 0.01 μg protein per lane). Representative samples from each dose group are shown. (b) Dose-correlated liver OTC activity at different time points post vector administration. Mean ± S.D. are shown (n=3-5 per group). (c) Dose-correlated vector genome copies in the liver of treated mice at different time points post vector administration. Mean ± S.D. are shown (n=3-5 per group). (d) Dose response showing the correlation of vector genome copies and liver OTC activity levels (*background activity in the spfash mice was subtracted). Data for 1×1011, 3×1010 and 1×1010 GC groups were based on week 13, and data for 3×109 and 1×109 GC groups were based on week 23. Mean ± S.D. are shown (n=3-5 per group).